Citizens JMP analyst Constantine Davides raised the firm’s price target on OptimizeRx (OPRX) to $24 from $23 and keeps an Outperform rating on the shares. OptimizeRx showed continuing momentum in Q3 and established formal guidance for 2026, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPRX:
- OptimizeRx Reports Strong Q3 Growth and Raises Guidance
- OptimizeRx: Strong Financial Performance and Promising Outlook Justify Buy Rating
- OptimizeRx reports Q3 EPS 20c, consensus 5c
- OptimizeRx raises FY25 revenue view to $105M-$109M from $104M-$108M
- OptimizeRx sees FY26 revenue $118M-$124M, consensus $119.19M